SCM
TEVA icon

Sterneck Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sterneck Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-28,207
Closed -$442K – 83
2019
Q1 		$442K Sell
28,207
-2,240
-7% -$39.5K 0.39% 50
2018
Q4 		$469K Sell
30,447
-55,351
-65% -$1.13M 0.46% 48
2018
Q3 		$1.85M Sell
85,798
-6,480
-7% -$150K 1.33% 23
2018
Q2 		$2.24M Sell
92,278
-57,629
-38% -$1.18M 1.55% 20
2018
Q1 		$2.56M Sell
149,907
-30,431
-17% -$594K 1.51% 23
2017
Q4 		$3.42M Sell
180,338
-31,860
-15% -$479K 2.05% 12
2017
Q3 		$3.73M Buy
212,198
+80,291
+61% +$1.81M 2.14% 11
2017
Q2 		$4.38M Buy
131,907
+6,702
+5% +$207K 2.62% 8
2017
Q1 		$4.02M Buy
125,205
+50,713
+68% +$1.73M 2.39% 9
2016
Q4 		$2.7M Buy
74,492
+56,477
+313% +$2.25M 1.74% 16
2016
Q3 		$829K Sell
18,015
-2,535
-12% -$132K 0.55% 63
2016
Q2 		$1.03M Buy
20,550
+1,400
+7% +$74.5K 0.69% 49
2016
Q1 		$1.02M Buy
19,150
+12,150
+174% +$713K 0.72% 42
2015
Q4 		$459K Sell
7,000
-5,550
-44% -$343K 0.29% 73
2015
Q3 		$709K Sell
12,550
-31,966
-72% -$2.07M 0.47% 54
2015
Q2 		$2.63M Buy
44,516
+5,236
+13% +$323K 1.45% 23
2015
Q1 		$2.45M Sell
39,280
-3,779
-9% -$220K 1.32% 29
2014
Q4 		$2.48M Buy
43,059
+370
+0.9% +$20.6K 1.47% 25
2014
Q3 		$2.29M Sell
42,689
-2,394
-5% -$127K 1.38% 29
2014
Q2 		$2.36M Sell
45,083
-4,375
-9% -$224K 1.38% 26
2014
Q1 		$2.61M Buy
49,458
+4,669
+10% +$216K 1.42% 28
2013
Q4 		$1.79M Buy
44,789
+6,397
+17% +$252K 1.09% 35
2013
Q3 		$1.45M Buy
38,392
+150
+0.4% +$5.85K 0.92% 39
2013
Q2 		$1.5M Buy
+38,242
New +$1.49M 0.95% 36

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sterneck Capital Management's TEVA Position: Q2 2019 in Review

Sterneck Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 28,207 shares — an estimated $442K sold.

Sterneck Capital Management first reported a position in TEVA in Q2 2013 and held it in 24 quarters. The position peaked at $4.38M in Q2 2017. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Sterneck Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Sterneck Capital Management sold 28,207 Teva Pharmaceuticals shares in Q2 2019, an estimated $442K.
  • Sterneck Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Sterneck Capital Management's Teva Pharmaceuticals position peaked at $4.38M in Q2 2017.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Sterneck Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.